MedPath

Fasting-Associated Immune-metabolic Remission of Diabetes

Not Applicable
Completed
Conditions
Obesity
Type 2 Diabetes Mellitus
Interventions
Behavioral: weight loss by very low energy diet intake which may differ in protein or carbohydrate content
Registration Number
NCT05295160
Lead Sponsor
Charite University, Berlin, Germany
Brief Summary

People with a body mass index above 28 kg/m² and an onset of type 2 diabetes within the last 4 years had a remission (HbA1c \<6.5% without medication) of diabetes in over 80% upon weight loss of 15 kg. Longer duration of diabetes reduced the chance of remission. The investigators will test whether there is a difference in remission upon weight loss of 15 kg using formula low calorie diets between subjects with a diabetes duration of \<4 years vs. \>8 years and oral treatment as primary end points. The immune metabolic programming of circulating monocytes will be investigated in detail regarding trained innate immunity and the endocrine responses will be determined using meal challenge tests.

Detailed Description

A remission of type 2 diabetes can be achieved in over 80% of people with a diagnosis within the last 4 years and overweight or obesity by weight loss of 15 kg. The mechanisms involve an improvement of insulin sensitivity and thereby insulin requirements and a regain of the function of insulin secreting beta cells. Longer duration of type 2 diabetes appears to impair the capacity of beta cell to regenerate. At present it is not possibe to predict success of the weight loss at an early time point. The investigators therefore aim to identify early markers of responders. It is unclear how the weight loss induces the remission in responders. Immune cells are known to contribute to insulin resistance by regulating adipose tissue function and hepatic and skeletal muscle metabolism by releasing cytokines. The inborn immune system is known to adapt to external stimuli by the process of trained immunity and is thought to contribute to insulin resistance and the dysfunction of beta-cells. The investigation will analyze the programming state of innate immune cells in detail in the course of diabetes remission. In addition, islet hormone responses to challenge tests will be performed to assess their function in detail.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
52
Inclusion Criteria
  • Type 2 diabetes diagnosed less than 4 or over 8 years, before study,
  • BMI > 28 kg/m²,
  • willingness to follow weight loss diet,
Exclusion Criteria
  • consuming disease,
  • intolerance for very low calorie formula diet,
  • known severe hepatic disease or liver cirrhosis,
  • type 1 diabetes,
  • severe disease of kidney or heart,
  • advanced diabetic retinopathy,
  • intake of glucocorticoids,
  • drug or alcohol abuse,
  • weight loss of >5 kg in the last 3 month,
  • eating disorder

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
type 2 diabetes - more than 8 yearsweight loss by very low energy diet intake which may differ in protein or carbohydrate contentPatients with a duration of more than 8 years since diagnosis of type 2 diabetes, BMI \> 28 kg/m², non-insulin treated who agree to loose 15 kg body weight by eating a very low calorie formula diet of 800 kcal/day for men and 600 kcal/day for women. The duration of the diet is until the weight loss is achieved.
type 2 diabetes - less than 4 years durationweight loss by very low energy diet intake which may differ in protein or carbohydrate contentPatients with a duration of less than 4 years since diagnosis of type 2 diabetes, BMI \> 28 kg/m², non-insulin treated who agree to loose 15 kg body weight by eating a very low calorie formula diet of 800 kcal/day for men and 600 kcal/day for women. The duration of the diet is until the weight loss is achieved.
Primary Outcome Measures
NameTimeMethod
Concentration of fasting blood glucose < 126 mg/deciliter3 month

Remission of type 2 diabetes defined by a concentration of a fasting blood glucose \< 126 mg/deciliter without diabetes medication

Secondary Outcome Measures
NameTimeMethod
Immune-metabolic profile and programing of innate immunitybefore, after 7 days and after 3 month

Changes of cluster of differentiation 4/cluster of differentiation antigen 45 circulating immune cells in percent of CD4+ cells measured by flow cytometry in blood.

Concentrations of TNFalpha in pg/ml, changes of Momocyte Chemoattractant Protein-1 in pg/ml.

Composition of the microbiomebefore, after 7 days and after 3 month

Percent changes in firmicutes in stool,

Trial Locations

Locations (1)

Charité Campus Benjamin Franklin

🇩🇪

Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath